StockNews.com initiated coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a research report sent to investors on Wednesday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
Shares of Galmed Pharmaceuticals stock opened at $0.31 on Wednesday. The firm’s 50-day simple moving average is $0.37 and its 200-day simple moving average is $0.38. Galmed Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $5.47. The firm has a market cap of $1.58 million, a P/E ratio of -0.13 and a beta of 0.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last announced its quarterly earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share (EPS) for the quarter.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- What is a Dividend King?
- McDonald’s Stock: Balancing Value and Innovation
- Dividend Capture Strategy: What You Need to Know
- MarketBeat Week in Review – 6/17 – 6/21
- There Are Different Types of Stock To Invest In
- Sarepta Therapeutics Stock Soars on FDA Approval
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
